

**• Name:**

Sung Hwa Bae

**• Affiliation/Current Position:**

Daegu Catholic University Hospital/Prof

**• Country:**

South Korea

**• ICKSH2022 Presentation Title:**

Recent advances in the management of immune mediated TTP

**• Educational Background:**

1988 – 1994 Yeungnam University College of Medicine, Daegu, Korea

2002 – 2004 Graduate School (Master's Course), Yeungnam University  
College of Medicine, Daegu, Korea

2005 – 2007 Graduate School (Ph.D. Course), Yeungnam University College  
of Medicine, Daegu. Korea

**• Professional Experiences:**

Professor, Division of Hematology/Oncology,

Department of Internal Medicine, Catholic University of Daegu School of  
Medicine, Daegu, Korea

**• Professional Organizations**

Korean Society of Hematology

Korean Society of Hematopoietic Stem Cell Transplantation

**• Main Scientific Publications:**

Hong J, Ahn SY, Lee YJ, Lee JH, Han JW, Kim KH, Yhim HY, Nam SH, Kim HJ, Song J, Kim SH, Bang SM, Kim JS, Mun YC, Bae SH, Kim HK, Jang S, Park R, Choi HS, Kim I, Oh D; Korean Society of Hematology Thrombosis and Hemostasis Working Party. Updated recommendations for the treatment of venous thromboembolism. *Blood Res.* 2021;56:6-16.

Lee JH, Kim H, Joo YD, Lee WS, Bae SH, Zang DY, Kwon J, Kim MK, Lee J, Lee GW, Lee JH, Choi Y, Kim DY, Hur EH, Lim SN, Lee SM, Ryoo HM, Kim HJ, Hyun MS, Lee KH; Cooperative Study Group A for Hematology. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia. *J Clin Oncol* 2017;35:2754-63.

Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, Lee JH, Lee WS, Park JH, Bae SH, Hyun MS, Kim DY, Kim SD, Min YJ, Lee KH. Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine. *J Clin Oncol* 2013;31:701-9.

Lee JH, Joo YD, Kim H, Bae SH, Kim MK, Zang DY, Lee JL, Lee GW, Lee JH, Park JH, Kim DY, Lee WS, Ryoo HM, Hyun MS, Kim HJ, Min YJ, Jang YE, Lee KH. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. *Blood* 2011;118:3832-41.

Lee KH, Choi SJ, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Yun SC, Joo YD, Lee WS, Kang MJ, Kim H, Park JH, Bae SH, Ryoo HM, Kim MK, Hyun MS. Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors. *Am J Hematol* 2011;86:399-405.

Bae SH, Ryoo HM, Kim MK, Lee KH, Sin JI, Hyun MS. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. *Oncology Rep* 2008;19:1027-1032.

Bae SH, Ryoo HM, Do YR, Song HS, Kwon KY, Kim MK, Lee KH, Hyun MS, Lee WS, Hur IK, Baek JH, Park KU. A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer. *Lung cancer* 2008;59:76-80.

Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: Causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic Synergy. *Clin Cancer Res* 2007;13:341-349.

Kim SY, Lee SA, Ryoo HM, Lee KH, Hyun MS, Bae SH. Thalidomide for POEMS syndrome. *Ann Hematol* 2006;85:545-546.

Bae SH, Ryoo HM, Cho HS, Lee JL, Lee KH, Hyun MS. Meningeal Relapse in a Patient with Acute Promyelocytic Leukemia: A Case Report and Review of the Literature. *J Korean Med Sci* 2004;19:311-314.